Friday, 16 October 2026European Markets

PROACTIS SA Stock Bullish By 21% In The Last 5 Sessions

Loading stream...

french software solutions company proactis sa (cac 40: proac.pa), has received renewed confidence from investors, leading to an extraordinary 21.95% share price increase over five sessions - from eur0.08 to eur0.10. this spike stands out against modest gains seen by french index cac 40, which rose 0.65% after four consecutive days of increases, to eur7,432.777.

proactis sa's investment potential

proactis sa's closing price remains 35.14% lower than its 52-week high of eur0.15, offering investors a great opportunity for speculation that proactis could once more reach previous heights.

about proactis sa

proactis sa, formerly hubwoo, offers procurement and spend control solutions that integrate with financial systems to streamline purchasing. rebranded as proactis euro hedgeco limited in suresnes in france in 2019, the company now operates under this name.

proactis sa's profitability

examining proactis sa's profitability, its trailing 12-month earnings per share (eps) stands at eur-0.01, suggesting it is not currently profitable. furthermore, with a negative return on equity (roe) of -3.88% over the last year, it shows how it has struggled to generate positive shareholder equity returns.

investor strategy with proactis sa

prospective investors must closely track financial indicators and growth plans of companies like proactis sa in order to assess both risk and reward before investing.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com